Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.04+0.06 (+0.55%)
Close on Nov 17, 2026Market cap $5.40BP/E –Yield –
Gossamer Bio r&d expenses
Research and development expenses are spending on new products and technology.
Gossamer Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $163.96M, up 8.9% year over year. For fiscal 2025 it was $174.09M, up 25.7% from the year before. The highest annual figure on record is $174.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.09M | +25.7% |
| FY2024 | Dec 31, 2024 | $138.49M | +2.4% |
| FY2023 | Dec 31, 2023 | $135.30M | -20.8% |
| FY2022 | Dec 31, 2022 | $170.92M | +0.4% |
| FY2021 | Dec 31, 2021 | $170.27M | +5.9% |
| FY2020 | Dec 31, 2020 | $160.85M | +12.2% |
| FY2019 | Dec 31, 2019 | $143.40M | +159.4% |
| FY2018 | Dec 31, 2018 | $55.28M | +6104.6% |
| FY2017 | Dec 31, 2017 | $891.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.41M | -36.5% |
| Q1 FY2026 | Mar 31, 2026 | $43.08M | +13.2% |
| Q4 FY2025 | Dec 31, 2025 | $48.94M | +35.5% |
| Q3 FY2025 | Sep 30, 2025 | $45.54M | +30.5% |
| Q2 FY2025 | Jun 30, 2025 | $41.58M | +18.5% |
| Q1 FY2025 | Mar 31, 2025 | $38.04M | +17.4% |
| Q4 FY2024 | Dec 31, 2024 | $36.11M | +20.5% |
| Q3 FY2024 | Sep 30, 2024 | $34.90M | +11.8% |
| Q2 FY2024 | Jun 30, 2024 | $35.09M | -3.4% |
| Q1 FY2024 | Mar 31, 2024 | $32.39M | -14.3% |
| Q4 FY2023 | Dec 31, 2023 | $29.97M | -27.8% |
| Q3 FY2023 | Sep 30, 2023 | $31.20M | -29.9% |
| Q2 FY2023 | Jun 30, 2023 | $36.31M | -14.7% |
| Q1 FY2023 | Mar 31, 2023 | $37.80M | -10.7% |
| Q4 FY2022 | Dec 31, 2022 | $41.51M | +1.4% |
| Q3 FY2022 | Sep 30, 2022 | $44.51M | +3.1% |
| Q2 FY2022 | Jun 30, 2022 | $42.58M | -3.9% |
| Q1 FY2022 | Mar 31, 2022 | $42.32M | +1.2% |
| Q4 FY2021 | Dec 31, 2021 | $40.93M | +5.2% |
| Q3 FY2021 | Sep 30, 2021 | $43.19M | +3.2% |
| Q2 FY2021 | Jun 30, 2021 | $44.32M | +14.6% |
| Q1 FY2021 | Mar 31, 2021 | $41.83M | +1.0% |
| Q4 FY2020 | Dec 31, 2020 | $38.91M | -8.7% |
| Q3 FY2020 | Sep 30, 2020 | $41.85M | +4.2% |
| Q2 FY2020 | Jun 30, 2020 | $38.68M | +8.4% |
| Q1 FY2020 | Mar 31, 2020 | $41.41M | +65.8% |
| Q4 FY2019 | Dec 31, 2019 | $42.60M | +64.6% |
| Q3 FY2019 | Sep 30, 2019 | $40.15M | +112.9% |
| Q2 FY2019 | Jun 30, 2019 | $35.68M | +349.9% |
| Q1 FY2019 | Mar 31, 2019 | $24.98M | +852.1% |
| Q4 FY2018 | Dec 31, 2018 | $25.87M | – |
| Q3 FY2018 | Sep 30, 2018 | $18.86M | – |
| Q2 FY2018 | Jun 30, 2018 | $7.93M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.62M | – |
See a number that looks wrong?